NASDAQ
Lumos Pharma, Inc. (LUMO) has a free cash flow growth of 21.54% as of Friday, May 29, 2026. This represents a 107.45% increase compared to its 12-month average of -289.02%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.